Thymosin Alpha 1 Modulates Immune Tolerance to Prevent Graft Rejection
Solution Overview
Problem
Current immunosuppressive agents used to prevent graft-versus-host disease (GVHD) in organ transplantation are associated with significant side effects such as nephrotoxicity and hepatotoxicity, highlighting the need for a treatment with improved toxicity profiles.
Innovation Solution
Thymosin alpha 1 is used for the prevention or treatment of GVHD, administered alone or in combination with immunosuppressive agents like prednisone, cyclosporin A, or FK506, to modulate immune responses and reduce graft rejection reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive agents (cyclosporin A, FK506, corticosteroids) are used to prevent GVHD, then graft rejection is suppressed, but nephrotoxicity and hepatotoxicity occur
Solution Approach 1:
Thymosin alpha-1 serves as an intermediary substance that modulates the immune system's response to allografts. Instead of directly suppressing immune function with toxic immunosuppressants, thymosin alpha-1 acts as a mediator that promotes immune tolerance through thymic peptide activity, thereby preventing graft rejection without causing nephrotoxicity or hepatotoxicity
Solution Approach 2:
The invention changes the pharmacological parameter from direct immunosuppression (with associated toxicity) to immune modulation via thymic peptides. Thymosin alpha-1 alters the immune response parameters by promoting regulatory T-cell function and inducing tolerance, thereby achieving graft protection with a fundamentally different mechanism that avoids organ toxicity
2Object-affected harmful factors
If thymosin alpha 1 is used to treat GVHD, then toxicity is reduced, but immune response modulation effectiveness must be maintained
Solution Approach 1:
Thymosin alpha-1 leverages the body's own thymic system and natural immune regulatory mechanisms to control GVHD. The peptide works by stimulating endogenous immune regulation pathways, particularly through enhancing regulatory T-cell function, allowing the immune system to self-regulate the rejection response without requiring external toxic suppression
Data Source
Figure 1A
Figure 1B~1C
Figure 2A~2B
AI summary
It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin.